PharmiWeb.com - Global Pharma News & Resources
05-Feb-2019

Trinity Partners Strengthens Leadership Team with Appointment of Kirsten Brady to Lead Marketing and Business Development

Global life sciences consulting firm Trinity Partners today announced it has hired new SVP, Commercial, Kirsten Brady, to lead the firm’s marketing and business development initiatives.

In this role, Brady will oversee marketing, business development, account management, sales operations, thought leadership as well as communication strategies for new services and platforms. She will work with Trinity executive leadership on the firm’s overarching growth strategy, U.S. and global expansion, and enhanced product offerings in data analytics, real-world evidence, health economics, and strategic advisory services. She will also be instrumental in launching and amplifying the firm’s technology-driven offerings. These new market offerings will enhance clients’ ability to deliver life-changing innovations to patients around the globe.

“Kirsten will add insights and experience to our leadership team and help fuel our growth in the next phase of Trinity’s evolution. We are excited to welcome such a dynamic, collaborative leader to the firm, who will be instrumental in defining and communicating our value proposition,” said Dave Fitzhenry, CEO, Trinity Partners.

Over the course of her career, Brady has built and led successful business development teams that accelerate and drive growth. Previously, Brady served as a Managing Director at FCB Health in New York, and as SVP, BD for Omnicom. She also worked for over nine years at Campbell Alliance/inVentiv Health (now Syneos Health), both as a management consultant and Head of Business Development and Marketing. She began her career in sales and marketing at AstraMerck and Pfizer, Inc. Brady has an M.B.A. in Marketing from The University of Michigan Ross School of Business, and a B.A. in English from Dartmouth College.

“Throughout my career, I’ve searched for ways to make an impact by connecting people, improving operational efficiencies, and identifying new business opportunities to accelerate growth,” said Brady. “I am truly excited about joining Trinity Partners at this time, to build upon our incredible legacy of success, expand our influence, and enhance the products and services we deliver to the life sciences industry.”

Brady’s hire marks the next step in Trinity’s mission and vision to lead transformation in the life sciences industry. In September 2018, Trinity acquired TGaS® Advisors, the leading benchmarking and advisory services firm for commercial organizations in the life sciences industry.

About TGaS Advisors

TGaS Advisors is the leading benchmarking and advisory services firm for commercial organizations in the life sciences industry. With a roster of more than 100 companies, including large, mid-tier, emerging and precommercial life sciences companies, TGaS provides robust comparative intelligence and collaborative network membership services. The team includes more than 50 experienced professionals, most with senior-level experience in the life sciences and related industries.

About Trinity Partners

Trinity Partners is a trusted life sciences strategy consulting firm that takes a personalized approach to working with pharmaceutical, biotech, medical device, and diagnostic clients worldwide to create tailored, evidence-based solutions that drive business strategy and impact bottom lines. Trinity has been named one of the Best Small Consulting Firms to Work For by Consulting Magazine in 2018 and has been named one of the Fastest Growing Firms by Consulting Magazine in 2016, 2017 and 2018. In 2018, Trinity also made the Forbes America’s Best Consulting Firms list and in 2016 Trinity was named as one of the Best Places to Work by the Boston Business Journal. Trinity is partnered with Parthenon Capital Partners, a leading, growth-oriented private equity firm. To learn more about Trinity Partners, click here.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190205005148/en/

Editor Details

Last Updated: 05-Feb-2019